MINI FUTURE SHORT - BRISTOL-MYERS SQUIBB | Market Closed - Bid/Ask 01:47:11 2024-07-11 pm EDT | After market 02:15:26 pm | |||
| 0.43 EUR | 0.00% |
|
0.435 | +1.16% |
| 1 month | +30.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.43 | 0.00% |
| 24-07-10 | 0.43 | -2.27% |
| 24-07-09 | 0.44 | -16.98% |
| 24-07-08 | 0.53 | -5.36% |
| 24-07-05 | 0.56 | +7.69% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 01:47 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PG1FKA |
| ISIN | DE000PG1FKA0 |
| Date issued | 2024-05-23 |
| Strike | 45.48 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.58 € |
|---|---|
| Lowest since issue | 0.28 € |
| Spread | 0.01 € |
| Spread % | 2.27% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.12
USD
Average target price
52.92
USD
Spread / Average Target
+28.70%
- Stock Market
- Certificates
- Certificat
